Scholar Rock (NASDAQ:SRRK) Director Sells $137,045.28 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Michael Gilman sold 2,544 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the transaction, the director owned 59,511 shares in the company, valued at $3,205,857.57. This trade represents a 4.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded up $0.48 during trading hours on Monday, reaching $55.36. 1,182,357 shares of the stock traded hands, compared to its average volume of 1,407,918. The company’s 50-day simple moving average is $48.43 and its two-hundred day simple moving average is $46.59. The company has a market capitalization of $6.63 billion, a P/E ratio of -15.42 and a beta of 0.67. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $56.54. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter last year, the company posted ($0.67) EPS. Equities research analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Institutional Investors Weigh In On Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Scholar Rock by 609.3% in the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after purchasing an additional 5,831 shares during the last quarter. Millennium Management LLC raised its position in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Scholar Rock by 25.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares during the period. Finally, Strs Ohio bought a new position in shares of Scholar Rock in the first quarter worth about $77,000. Institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRRK. Wedbush increased their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. JPMorgan Chase & Co. upped their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group began coverage on Scholar Rock in a research note on Monday, April 20th. They set a “buy” rating and a $62.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).